Zheng Quan Shi Bao Wang·2025-11-28 03:09Core Insights - Nocare Biopharma announced the completion of the first patient dosing in the global Phase II clinical trial of its novel TYK2 inhibitor, Soficitinib, for the treatment of nodular prurigo [1][2] - Soficitinib is designed to treat various T-cell related autoimmune diseases, with a strong focus on dermatological conditions such as atopic dermatitis, vitiligo, nodular prurigo, and urticaria [1] - The global market for nodular prurigo treatment is projected to grow from $2 billion in 2024 to $3 billion by 2034, with approximately 10 million patients affected worldwide [1] Company Developments - Nocare Biopharma's product pipeline covers ten autoimmune diseases, with a significant emphasis on dermatological diseases [2] - Soficitinib has demonstrated excellent efficacy and safety in Phase II clinical studies for moderate to severe atopic dermatitis, and the research was selected for a prominent oral presentation at the American Academy of Dermatology annual meeting [2] - The company is accelerating its global clinical development to provide innovative treatment solutions for more autoimmune patients [2]